Skip to Content

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

The CAPTIVATE study is a phase II international study that evaluates the efficacy of a combination treatment of ibrutinib and venetoclax in a fixed duration as a first-line treatment for chronic lymphocytic leukemia (CLL). At ASH 2023, Professor Paolo Ghia presented the follow-up at five years of the study, on which he will elaborate in this MEDtalk.

Paolo Ghia

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top